PAT Surges 42%, but Insurance Underwriting Deteriorates

The headline profit of ₹1,789 Cr (+42% YoY) masks a story of insurance deterioration that the market understood immediately. On day 1 post-result, the stock fell 1.25%; by day 3 it had given back 2.55%. That tape was not noise — it was the market's verdict on what the quarter really was: a holding company with strong capital but an insurance arm in crisis.

Cholamandalam's insurance operations, which account for 60%+ of the business, are facing an acute underwriting crisis. The motor segment — 70% of the insurance book — saw its OD (Own-Damage) loss ratio spike to 86%+ in Q1 from 80%+ in FY2026, moving in the opposite direction of management's stated target of 71–73%. The combined ratio deteriorated to 120.4% from 115.2%, a four-quarter uptrend (FY25: 110% → FY26: 115.2% → Q1 FY27: 120.4%) that shows the damage is structural, not one-time.

Management blamed a large fire loss (₹12.4 Cr net) and elevated motor reserve strengthening. That loss explains part of the 5.2pp deterioration, but not all of it. The underlying insurance underwriting — claims inflation in motor, health pricing leakage, commercial lines soft pricing — is what's driving the combined ratio higher. The motor OD crisis is the core problem.

Motor OD guidance missed. In the prior quarter, management signalled that 7–8% pricing corrections would improve the motor OD loss ratio over 6 months. That didn't happen; the ratio deteriorated further to 86%+. Now the target is vaguely 'a couple of quarters' to stabilize in the high-70s, with no firm milestones.

Health strategy shifted to profitability-first. Prior guidance implied growth in the health segment. Q1 FY27 shows an intentional decline via pricing corrections in PSU bank platforms and selective standalone policies. This is a strategic retreat, not a pivot — the company is building 'capabilities from the ground up' but sacrificing volume.

Combined ratio deterioration is a trend, not a blip. The four-quarter progression (FY25: 110% → FY26: 115.2% → Q1 FY27: 120.4%) shows compressing insurance margins, with no clear bottom in sight. Claims inflation in motor and health is outpacing pricing power.

ROE guidance not reaffirmed. Prior guidance targeted 15%+ ROE recovery. This quarter, no forward guidance on ROE or profitability; management focused on operational fixes (motor NCB, portfolio mix, ACS control) rather than earnings targets.

The stock was priced at ₹1,598 on the day before the result (Aug 14, 2026). On day 1 post-announcement, it fell 1.25% to ₹1,578. By day 3, the decline had deepened to –2.55%. This was not a pop-and-fade; the negative verdict held. As of today (Aug 20, 2026), the stock trades at ₹1,574.2, with a trend rated bearish. It sits below its SMA50 (₹1,589.48) and SMA200 (₹1,673.83), a sign that downside momentum is intact.

In absolute terms, the stock is down 23.73% from its all-time high of ₹2,064 but up 20.63% from its 52-week low. The drawdown from ATH is substantial, suggesting some repricing of the risk. However, the fact that it remains below the 50-day and 200-day moving averages indicates that the market has not found a floor yet.

On ownership, the trend is telling: FII have reduced exposure from 18.32% (Q1 FY26) to 13.00% (Q1 FY27), a decline of 5.32 percentage points. DII remain steady at 26.89%, and promoters are stable at 46.43%. The FII exit is noteworthy — it suggests that foreign investors are reducing exposure to the underwriting deterioration story, particularly the motor OD crisis and the Supreme Court tail risk. The post-result selloff aligns with this underlying flow shift.

In sum: the market understands the quarter. The negative tape is not a mistake.